In silico modeling for the nonlinear absorption kinetics of UK-343,664: A P-gp and CYP3A4 substrate

Molecular Pharmaceutics

Volumn 9, Issue 3, 2012, Pages 492-504

  Abuasal, Bilal S ^a   Bolger, Michael B ^b   Walker, Don K ^c   Kaddoumi, Amal ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^b Simulations Plus Inc   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

GastroPlus; in silico modeling; intestinal metabolism; nonlinear pharmacokinetics; P glycoprotein

Indexed keywords

CYTOCHROME P450 3A4; GLYCOPROTEIN P; PHOSPHODIESTERASE V INHIBITOR; UK 343664; UNCLASSIFIED DRUG;

ALLOMETRY; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COMPLEX FORMATION; COMPUTER MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG SOLUBILITY; FIRST PASS EFFECT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NONLINEAR SYSTEM; PRIORITY JOURNAL; RAT; SIMULATION;

ABSORPTION; ANIMALS; CYTOCHROME P-450 CYP3A; HUMANS; INTESTINAL ABSORPTION; KINETICS; MALE; P-GLYCOPROTEIN; PIPERAZINES; PYRIMIDINONES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84858016380     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp200275j     Document Type: Article

References (64)

1. Hidalgo, I. J. Assessing the absorption of new pharmaceuticals Curr. Top. Med. Chem. 2001, 1 (5) 385-401
2. Levet-Trafit, B.; Gruyer, M. S.; Marjanovic, M.; Chou, R. C. Estimation of oral drug absorption in man based on intestine permeability in rats Life Sci. 1996, 58 (24) PL359-PL363
3. Chan, K. K.; Gibaldi, M. Evaluating drug absorption after oral administration. Some problems and some solutions Eur. J. Clin. Pharmacol. 1984, 26 (2) 255-259 (Pubitemid 14130439)
4. Burton, P. S.; Goodwin, J. T.; Vidmar, T. J.; Amore, B. M. Predicting drug absorption: how nature made it a difficult problem J. Pharmacol. Exp. Ther. 2002, 303 (3) 889-895 (Pubitemid 35424368)
5. Benet, L. Z. Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System Basic Clin. Pharmacol. Toxicol. 2010, 106 (3) 162-167
6. Hurst, S.; Loi, C. M.; Brodfuehrer, J.; El-Kattan, A. Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans Expert Opin. Drug Metab. Toxicol. 2007, 3 (4) 469-489 (Pubitemid 351324958)
7. Abuzarur-Aloul, R.; Gjellan, K.; Sjolund, M.; Graffner, C. Critical dissolution tests of oral systems based on statistically designed experiments. III. In vitro/in vivo correlation for multiple-unit capsules of paracetamol based on PLS modeling Drug Dev. Ind. Pharm. 1998, 24 (4) 371-383 (Pubitemid 28204507)
8. Fujioka, Y.; Kadono, K.; Fujie, Y.; Metsugi, Y.; Ogawara, K.; Higaki, K.; Kimura, T. Prediction of oral absorption of griseofulvin, a BCS class II drug, based on GITA model: utilization of a more suitable medium for in-vitro dissolution study J. Controlled Release 2007, 119 (2) 222-228 (Pubitemid 46754508)
9. Takano, R.; Furumoto, K.; Shiraki, K.; Takata, N.; Hayashi, Y.; Aso, Y.; Yamashita, S. Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation Pharm. Res. 2008, 25 (10) 2334-2344
10. He, X.; Sugawara, M.; Kobayashi, M.; Takekuma, Y.; Miyazaki, K. An in vitro system for prediction of oral absorption of relatively water-soluble drugs and ester prodrugs Int. J. Pharm. 2003, 263 (1 - 2) 35-44 (Pubitemid 37087930)
11. Zhao, Y. H.; Abraham, M. H.; Le, J.; Hersey, A.; Luscombe, C. N.; Beck, G.; Sherborne, B.; Cooper, I. Rate-limited steps of human oral absorption and QSAR studies Pharm. Res. 2002, 19 (10) 1446-1457 (Pubitemid 35266548)
12. Kobayashi, M.; Sada, N.; Sugawara, M.; Iseki, K.; Miyazaki, K. Development of a new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract Int. J. Pharm. 2001, 221 (1 - 2) 87-94 (Pubitemid 32524038)
13. Ribadeneira, M. D.; Aungst, B. J.; Eyermann, C. J.; Huang, S. M. Effects of structural modifications on the intestinal permeability of angiotensin II receptor antagonists and the correlation of in vitro, in situ, and in vivo absorption Pharm. Res. 1996, 13 (2) 227-233 (Pubitemid 26074193)
14. Zhao, Y. H.; Le, J.; Abraham, M. H.; Hersey, A.; Eddershaw, P. J.; Luscombe, C. N.; Butina, D.; Beck, G.; Sherborne, B.; Cooper, I.; Platts, J. A. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors J. Pharm. Sci. 2001, 90 (6) 749-784 (Pubitemid 32530451)
15. Oostendorp, R. L.; Beijnen, J. H.; Schellens, J. H. The biological and clinical role of drug transporters at the intestinal barrier Cancer Treat. Rev. 2009, 35 (2) 137-147
16. Shirasaka, Y.; Sakane, T.; Yamashita, S. Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane J. Pharm. Sci. 2008, 97 (1) 553-565
17. del Amo, E. M.; Heikkinen, A. T.; Monkkonen, J. In vitro-in vivo correlation in P-glycoprotein mediated transport in intestinal absorption Eur. J. Pharm. Sci. 2009, 36 (2 - 3) 200-211
18. Lennernas, H. Intestinal permeability and its relevance for absorption and elimination Xenobiotica 2007, 37 (10 - 11) 1015-1051 (Pubitemid 350035536)
19. Sugano, K.; Kansy, M.; Artursson, P.; Avdeef, A.; Bendels, S.; Di, L.; Ecker, G. F.; Faller, B.; Fischer, H.; Gerebtzoff, G.; Lennernaes, H.; Senner, F. Coexistence of passive and carrier-mediated processes in drug transport Nat. Rev. Drug Discovery 2010, 9 (8) 597-614
20. Nakanishi, Y.; Matsushita, A.; Matsuno, K.; Iwasaki, K.; Utoh, M.; Nakamura, C.; Uno, Y. Regional distribution of cytochrome p450 mRNA expression in the liver and small intestine of cynomolgus monkeys Drug Metab. Pharmacokinet. 2010, 25 (3) 290-297
21. Kagan, L.; Dreifinger, T.; Mager, D. E.; Hoffman, A. Role of p-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats Drug Metab. Dispos. 2010, 38 (9) 1560-1566
22. Ingelfinger, F. J. Regional absorption Am. J. Surg. 1967, 114 (3) 388-392
23. Paine, M. F.; Khalighi, M.; Fisher, J. M.; Shen, D. D.; Kunze, K. L.; Marsh, C. L.; Perkins, J. D.; Thummel, K. E. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism J. Pharmacol. Exp. Ther. 1997, 283 (3) 1552-1562 (Pubitemid 28016533)
24. Kalitsky-Szirtes, J.; Shayeganpour, A.; Brocks, D. R.; Piquette-Miller, M. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats Drug Metab. Dispos. 2004, 32 (1) 20-27 (Pubitemid 38112531)
25. Cong, D.; Doherty, M.; Pang, K. S. A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism Drug Metab. Dispos. 2000, 28 (2) 224-235 (Pubitemid 30069008)
26. Paine, M. F.; Davis, C. L.; Shen, D. D.; Marsh, C. L.; Raisys, V. A.; Thummel, K. E. Can oral midazolam predict oral cyclosporine disposition? Eur. J. Pharm. Sci. 2000, 12 (1) 51-62
27. Bouer, R.; Barthe, L.; Philibert, C.; Tournaire, C.; Woodley, J.; Houin, G. The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac Fundam. Clin. Pharmacol. 1999, 13 (4) 494-500 (Pubitemid 32250275)
28. Stephens, R. H.; O'Neill, C. A.; Warhurst, A.; Carlson, G. L.; Rowland, M.; Warhurst, G. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia J. Pharmacol. Exp. Ther. 2001, 296 (2) 584-591 (Pubitemid 32112489)
29. Sun, H.; Pang, K. S. Permeability, transport, and metabolism of solutes in Caco-2 cell monolayers: a theoretical study Drug Metab. Dispos. 2008, 36 (1) 102-123
30. Knight, B.; Troutman, M.; Thakker, D. R. Deconvoluting the effects of P-glycoprotein on intestinal CYP3A: a major challenge Curr. Opin. Pharmacol. 2006, 6 (5) 528-532 (Pubitemid 44340667)
31. Benet, L. Z. The drug transporter-metabolism alliance: uncovering and defining the interplay Mol. Pharmaceutics 2009, 6 (6) 1631-1643
32. Darwish, M.; Kirby, M.; Robertson, P., Jr.; Tracewell, W.; Jiang, J. G. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate J. Clin. Pharmacol. 2007, 47 (3) 343-350 (Pubitemid 46294716)
33. Zhang, Y.; Benet, L. Z. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein Clin. Pharmacokinet. 2001, 40 (3) 159-168 (Pubitemid 32324448)
34. Tubic, M.; Wagner, D.; Spahn-Langguth, H.; Bolger, M. B.; Langguth, P. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect Pharm. Res. 2006, 23 (8) 1712-1720 (Pubitemid 44200533)
35. Thompson, K. L.; Vincent, S. H.; Miller, R. R.; Colletti, A. E.; Alvaro, R. F.; Wallace, M. A.; Feeney, W. P.; Chiu, S. H. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs Drug Metab. Dispos. 1997, 25 (10) 1113-1118 (Pubitemid 27446579)
36. Umehara, K. I.; Nakamata, T.; Suzuki, K.; Noguchi, K.; Usui, T.; Kamimura, H. Pharmacokinetics of YK754, a novel If channel inhibitor in rats, dogs and humans Eur. J. Drug Metab. Pharmacokinet. 2008, 33 (2) 117-127
37. Chan, L. M.; Lowes, S.; Hirst, B. H. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability Eur. J. Pharm. Sci. 2004, 21 (1) 25-51 (Pubitemid 38050202)
38. Abel, S.; Beaumont, K. C.; Crespi, C. L.; Eve, M. D.; Fox, L.; Hyland, R.; Jones, B. C.; Muirhead, G. J.; Smith, D. A.; Venn, R. F.; Walker, D. K. Potential role for P-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man Xenobiotica 2001, 31 (8 - 9) 665-676 (Pubitemid 32826398)
39. Huang, W.; Lee, S. L.; Yu, L. X. Mechanistic approaches to predicting oral drug absorption AAPS J. 2009, 11 (2) 217-224
40. Kuentz, M.; Nick, S.; Parrott, N.; Rothlisberger, D. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study Eur. J. Pharm. Sci. 2006, 27 (1) 91-99 (Pubitemid 41728259)
41. Fernandez-Teruel, C.; Gonzalez-Alvarez, I.; Navarro-Fontestad, C.; Garcia-Arieta, A.; Bermejo, M.; Casabo, V. G. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: Part II. Non-linear kinetics Eur. J. Pharm. Sci. 2009, 36 (1) 147-156
42. Parrott, N.; Lave, T. Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA Eur. J. Pharm. Sci. 2002, 17 (1 - 2) 51-61 (Pubitemid 35287171)
43. Willmann, S.; Lippert, J.; Schmitt, W. From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools Expert Opin. Drug Metab. Toxicol. 2005, 1 (1) 159-168
44. Jadhav, G. S.; Vavia, P. R. Physicochemical, in silico and in vivo evaluation of a danazol-beta-cyclodextrin complex Int. J. Pharm. 2008, 352 (1 - 2) 5-16 (Pubitemid 351284585)
45. Darwich, A. S.; Neuhoff, S.; Jamei, M.; Rostami-Hodjegan, A. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model Curr. Drug Metab. 2010, 11 (9) 716-729
46. Tam, D.; Sun, H.; Pang, K. S. Influence of P-glycoprotein, transfer clearances, and drug binding on intestinal metabolism in Caco-2 cell monolayers or membrane preparations: a theoretical analysis Drug Metab. Dispos. 2003, 31 (10) 1214-1226 (Pubitemid 37152972)
47. Yu, L. X.; Lipka, E.; Crison, J. R.; Amidon, G. L. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption Adv. Drug Delivery Rev. 1996, 19 (3) 359-376 (Pubitemid 26227526)
48. Agoram, B.; Woltosz, W. S.; Bolger, M. B. Predicting the impact of physiological and biochemical processes on oral drug bioavailability Adv. Drug Delivery Rev. 2001, 50 (Suppl. 1) S41-S67
49. Zhang, X.; Lionberger, R. A.; Davit, B. M.; Yu, L. X. Utility of physiologically based absorption modeling in implementing Quality by Design in drug development AAPS J. 2011, 13 (1) 59-71
50. Kaddoumi, A.; Fleisher, D.; Heimbach, T.; Li, L. Y.; Cole, S. Factors influencing regional differences in intestinal absorption of UK-343,664 in rat: possible role in dose-dependent pharmacokinetics J. Pharm. Sci. 2006, 95 (2) 435-445 (Pubitemid 43241984)
51. Walker, D. K.; Beaumont, K. C.; Comby, P.; Evans, K. M.; Gedge, J. I.; Halliday, R. C.; Roffey, S. J.; Wright, P. A. Pharmacokinetics and metabolism of a selective PDE5 inhibitor (UK-343,664) in rat and dog Xenobiotica 2001, 31 (8 - 9) 651-664 (Pubitemid 32826397)
52. Abuasal, B.; Sylvester, P. W.; Kaddoumi, A. Intestinal absorption of gamma-tocotrienol is mediated by Niemann-Pick C1-like 1: in situ rat intestinal perfusion studies Drug Metab. Dispos. 2010, 38 (6) 939-945
53. Volgyi, G.; Baka, E.; Box, K. J.; Comer, J. E.; Takacs-Novak, K. Study of pH-dependent solubility of organic bases. Revisit of Henderson-Hasselbalch relationship Anal. Chim. Acta 2010, 673 (1) 40-46
54. Avdeef, A.; Bendels, S.; Di, L.; Faller, B.; Kansy, M.; Sugano, K.; Yamauchi, Y. PAMPA-critical factors for better predictions of absorption J. Pharm. Sci. 2007, 96 (11) 2893-2909 (Pubitemid 350221191)
55. Zakeri-Milani, P.; Valizadeh, H.; Tajerzadeh, H.; Azarmi, Y.; Islambolchilar, Z.; Barzegar, S.; Barzegar-Jalali, M. Predicting human intestinal permeability using single-pass intestinal perfusion in rat J. Pharm. Pharm. Sci. 2007, 10 (3) 368-379 (Pubitemid 350065177)
56. Kim, J. S.; Mitchell, S.; Kijek, P.; Tsume, Y.; Hilfinger, J.; Amidon, G. L. The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests Mol. Pharmaceutics 2006, 3 (6) 686-694 (Pubitemid 46087485)
57. Obach, R. S.; Baxter, J. G.; Liston, T. E.; Silber, B. M.; Jones, B. C.; MacIntyre, F.; Rance, D. J.; Wastall, P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data J. Pharmacol. Exp. Ther. 1997, 283 (1) 46-58 (Pubitemid 27438945)
58. Poulin, P.; Theil, F. P. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution J. Pharm. Sci. 2002, 91 (1) 129-156 (Pubitemid 34074473)
59. Rodgers, T.; Rowland, M. Mechanistic approaches to volume of distribution predictions: understanding the processes Pharm. Res. 2007, 24 (5) 918-933 (Pubitemid 46675393)
60. Lave, T.; Coassolo, P.; Reigner, B. Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations Clin. Pharmacokinet. 1999, 36 (3) 211-231 (Pubitemid 29178759)
61. Mouly, S.; Paine, M. F. P-glycoprotein increases from proximal to distal regions of human small intestine Pharm. Res. 2003, 20 (10) 1595-1599 (Pubitemid 37268274)
62. Bruyere, A.; Decleves, X.; Bouzom, F.; Ball, K.; Marques, C.; Treton, X.; Pocard, M.; Valleur, P.; Bouhnik, Y.; Panis, Y.; Scherrmann, J. M.; Mouly, S. Effect of Variations in the Amounts of P-Glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the Human Small Intestine on PBPK Models for Predicting Intestinal First Pass Mol. Pharmaceutics 2010, 7 (5) 1596-1607
63. Zhang, Y.; Benet, L. Z. Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers Pharm. Res. 1998, 15 (10) 1520-1524 (Pubitemid 28465736)
64. Korjamo, T.; Kemilainen, H.; Heikkinen, A. T.; Monkkonen, J. Decrease in intracellular concentration causes the shift in Km value of efflux pump substrates Drug Metab. Dispos. 2007, 35 (9) 1574-1579 (Pubitemid 47296050)